This clinical trial is focused on studying the effects of a new treatment called IMA402 on patients with solid tumors. Solid tumors are abnormal masses of tissue that usually do not contain cysts or liquid areas. The treatment being tested, IMA402, is a special type of protein known as a bispecific T cell receptor-antibody fusion protein, which is designed to help the body’s immune system target and fight cancer cells more effectively. The trial will also involve the use of Human Serum Albumin and Tocilizumab, which are solutions given through an intravenous infusion, meaning they are administered directly into the bloodstream.
The purpose of this study is to evaluate the safety, tolerability, and anti-tumor activity of IMA402 in patients whose solid tumors have returned or are resistant to standard treatments. The study will be conducted in two phases. In the first phase, researchers will determine the most appropriate dose of IMA402 that patients can tolerate. In the second phase, the focus will be on assessing how well the treatment works in reducing the size of the tumors.
Participants in the study will receive the treatment through an intravenous infusion, and their health will be closely monitored by the research team. The study aims to gather information on any side effects experienced by the participants and how the treatment affects their tumors. This information will help researchers understand the potential benefits and risks of IMA402 for treating solid tumors.
Germany 
The Netherlands 
